
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. is strategically advancing its OST-HER2 program towards potential accelerated approval, having successfully completed a Type C meeting with the FDA, which has clarified the path for a Biologics License Application (BLA) filing for metastatic osteosarcoma. Additionally, the company achieved critical regulatory alignment with the UK Medicines and Healthcare products Regulatory Agency (MHRA), marking a significant milestone in the journey towards conditional approval in the UK. The ongoing efforts to leverage immune-response biomarker data as a efficacy endpoint in clinical trials further enhance the outlook for OST-HER2, positioning the company favorably for future clinical and regulatory successes.
Bears say
OS Therapies Inc. faces significant challenges due to the inherent complexities associated with osteosarcoma, as evidenced by its poor responsiveness to receptor-level HER2 inhibition and antibody therapies. Furthermore, the disease's immunologically "cold" and genetically unstable nature poses a considerable hurdle for the development and commercialization of effective treatments. These factors collectively contribute to a concerning outlook regarding the company's ability to achieve sustainable growth and market success in a competitive biopharmaceutical landscape.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares